Literature DB >> 15718486

Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies.

David J Warren1, Johan Bjerner, Elisabeth Paus, Ole P Børmer, Kjell Nustad.   

Abstract

BACKGROUND: Heterophilic antibodies are a common source of interference in immunometric assays. We tested the hypothesis that the incidence of such interference could be decreased by use of a recombinant in vivo-biotinylated single-chain antibody (scFv) as the capture reagent.
METHODS: We established three assays for carcinoembryonic antigen (CEA) with the capture antibody either chemically biotinylated whole monoclonal T84.66 immunoglobulin, a corresponding F(ab')2 fragment, or a site-specifically biotinylated T84.66-derived single-chain antibody (scFv). Antibodies were attached to streptavidin-coated microplates. A common europium-labeled anti-CEA tracer monoclonal antibody was used. The F(ab')2 assay used a buffer that contained bovine immunoglobulin and aggregated irrelevant monoclonal antibody MAK33 as blocking agents. The whole T84.66 immunoglobulin and scFv assays were performed without addition of blocking agents. From a previous study of 11 261 sera, we tested 390 samples that had displayed heterophilic antibody interference and 179 samples that had not.
RESULTS: After correction for bias and analytical variation [2.56 x SD (from the precision profile)], 383 samples displayed significantly different values (>1 microg/L) in the whole T84.66-based assay and the F(ab')2 assay. In contrast, only nine samples showed falsely high CEA concentrations in the scFv assay. After blocking agents were added to the assay buffer, eight of the nine samples displayed results equivalent to those of the F(ab')2 assay, and sample dilution produced equivalent results for the remaining sample.
CONCLUSION: Their ability to be site-specifically biotinylated and their relative resistance to heterophilic antibody interference indicate that single-chain antibodies may be useful solid-phase reagents in immunometric assays.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718486     DOI: 10.1373/clinchem.2004.046979

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

1.  Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.

Authors:  Nathalie Scholler; Barbara Garvik; Travis Quarles; Shaoyi Jiang; Nicole Urban
Journal:  J Immunol Methods       Date:  2006-10-30       Impact factor: 2.303

2.  Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum.

Authors:  Bhaswati Barat; Anna M Wu
Journal:  Biomol Eng       Date:  2007-02-15

3.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Authors:  Merete Thune Wiiger; Hege B Gehrken; Øystein Fodstad; Gunhild M Maelandsmo; Yvonne Andersson
Journal:  Cancer Immunol Immunother       Date:  2010-07-16       Impact factor: 6.968

Review 4.  Pre-existing Antibody: Biotherapeutic Modality-Based Review.

Authors:  Boris Gorovits; Adrienne Clements-Egan; Mary Birchler; Meina Liang; Heather Myler; Kun Peng; Shobha Purushothama; Manoj Rajadhyaksha; Laura Salazar-Fontana; Crystal Sung; Li Xue
Journal:  AAPS J       Date:  2016-01-28       Impact factor: 4.009

5.  Fiber-optic microsphere-based antibody array for the analysis of inflammatory cytokines in saliva.

Authors:  Timothy M Blicharz; Walter L Siqueira; Eva J Helmerhorst; Frank G Oppenheim; Philip J Wexler; Frédéric F Little; David R Walt
Journal:  Anal Chem       Date:  2009-03-15       Impact factor: 6.986

6.  Characterization of canine anti-mouse antibodies highlights that multiple strategies are needed to combat immunoassay interference.

Authors:  Daniel Bergman; Anders Larsson; Helene Hansson-Hamlin; Emma Åhlén; Bodil Ström Holst
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

Review 7.  Phage display: a powerful technology for the generation of high specificity affinity reagents from alternative immune sources.

Authors:  William J J Finlay; Laird Bloom; Orla Cunningham
Journal:  Methods Mol Biol       Date:  2011

8.  Phage Display: A Powerful Technology for the Generation of High-Specificity Affinity Reagents from Alternative Immune Sources.

Authors:  William J J Finlay; Laird Bloom; Joanne Grant; Edward Franklin; Deirdre Ní Shúilleabháin; Orla Cunningham
Journal:  Methods Mol Biol       Date:  2017

9.  Antibody fragment expression and purification.

Authors:  Dimana Dimitrova; Vidita Choudhry; Christopher C Broder
Journal:  Methods Mol Biol       Date:  2009

10.  Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Authors:  Y Andersson; O Engebraaten; S Juell; S Aamdal; P Brunsvig; Ø Fodstad; S Dueland
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.